Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nevada for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nevada only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nevada (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Emily Guerard (NPI 1417190414)

Field	Value
Entity Type	Individual
Organization	Emily Guerard
Address	5423 Reno Corporate Dr.
City	Reno
State	NV
ZIP	89511
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 7, 2009

Payer Source	Total Paid
Medicare	$1.3M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-only biller: Total Medicare revenue is $1.3M while Medicaid revenue is listed as none, so payer mix is highly concentrated with Medicare as the dominant — and sole reported — public payer. That single-payer profile should be considered when comparing revenue trends or negotiating with commercial plans because there is no Medicaid activity on file to balance Medicare exposure.

Revenue concentration is high: the precomputed top 3 Medicare codes account for 74.8% of this provider's total Medicare revenue, driven primarily by J9271, J9144, and 99214. Those three codes together indicate most Medicare dollars come from a small set of drug and office-visit services rather than a broad portfolio of low-revenue items.

The provider’s Medicare billing is commercially oriented toward high-cost oncology infusions: J9271 (pembrolizumab) generated $576.2K in revenue (44.2% of total Medicare revenue) with 13.4K claims at $43 avg paid/claim, and J9144 (daratumumab) generated $294.1K (22.5%) with 7.7K claims at $38 avg paid/claim. These high-dollar drug codes, coupled with chemotherapy administration codes such as 96413 (376 claims, $38.4K revenue) and infusion-related codes like 96365, are consistent with a clinic-based hematology/oncology infusion practice.

Clinical evaluation-and-management activity is a standout: 99214 produced $105.2K (8.1% of Medicare revenue) from 1.1K claims at $97 avg paid/claim and is labeled an extreme outlier (ranks #9331 of 479517, 98th percentile). 99215 is also notably above typical national volume (394 claims, $54.8K revenue, 4.2% of revenue; 98th percentile), which together indicate unusually high E/M volumes relative to national peers and suggest a busy outpatient practice with significant follow-up care.

Competitive standing for the principal drug therapies is modest nationally: J9271 ranks #806 of 1841 providers (55th percentile) and J9144 ranks #320 of 615 providers (46th percentile), both described as typical, unremarkable volumes. In other words, while these drug categories drive most revenue, this provider’s share of national infusion volume for those drugs is not dominant and sits near the middle of peer distributions.

Support services and onsite procedures are substantial: high-percentile procedural activity includes blood draws (36415: 876 claims, $7K revenue; 96th percentile) and CBC testing (85025: 961 claims, $6.7K revenue; 92nd percentile), indicating routine in-office phlebotomy and lab workflows. Similarly, infusion-related add-ons and administration codes such as 96375 (531 claims, $6.4K revenue; 89th percentile) and 96413 (83rd percentile) support a practice model that co-locates treatment delivery and ancillary services.

The provider’s drug mix spans monoclonal antibodies and supportive agents: beyond pembrolizumab and daratumumab, the profile includes denosumab J0897 (5K claims, $89.6K revenue, 6.9%) and trastuzumab biosimilar Q5117 (1.7K claims, $35.9K revenue, 2.8%), reflecting a combination of cancer-directed biologics and bone-supportive therapy often used in oncology care. This mixture of high-cost immunotherapies and supportive pharmaceuticals is consistent with a hematology & oncology specialty treating solid tumors and hematologic malignancies in the outpatient setting.

Tenure and practice stability are indicated by the NPI: the provider was enumerated 2009-04-07 (~17 years ago), which suggests an established billing history and potential longitudinal patient panel that may explain persistent high E/M volumes and steady infusion-based revenue streams. Analysts should consider this tenure when assessing referral patterns, patient retention, and growth potential in the local Reno market.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

50 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	13,400	$40	$576.2K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	7,740	$40	$294.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,090	$100	$105.2K
J0897	Injection, denosumab, 1 mg	4,980	$20	$89.6K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	390	$140	$54.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	380	$100	$38.4K
Q5117	Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg	1,710	$20	$35.9K
Q5111	Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg	250	$110	$27.2K
99233	The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the…	90	$90	$8.7K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	110	$60	$7.3K

Showing 1–10 of 50

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 50 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nevada Distribution

Emily Guerard — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nevada

Full comparison — all codes billed, vs. state median

50 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	16	40	13,000	$40	$625.8K
J9144	10	10	9,180	$40	$445.4K
J0897	25	70	3,630	$20	$94.6K
Q5111	9	10	400	$110	$46.4K
Q5117	1	10	1,710	$20	$36.1K
99233	697	1,150	150	$90	$26.8K
96413	14	70	210	$100	$23.7K
84443	54	80	50	$20	$22.7K
80053	46	100	160	$10	$22.2K
99214	93	3,610	110	$80	$19K

Showing 1–10 of 50

Related Providers

Other providers that share a Tax Identification Number (TIN) with Emily Guerard, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Southwest Health Center, Inc	WI	Critical Access Hospital	$225.5K	$8.3M
Tejvir Singh	NV	Hematology & Oncology Physician	$2.5M	$280
Southwest Health Center, Inc.	WI	Rural Health Clinic/Center	$0	$2.3M
Santhosh Ambika	NV	Hematology & Oncology Physician	$1.9M	$1.6K
Subramanyeswara Arekapudi	NV	Hematology & Oncology Physician	$1.7M	$0
Allison Dunne	WI	Physician Assistant	$1.4M	$0
Sowjanya Reganti	NV	Hematology & Oncology Physician	$1.3M	$5.3K
Chivonne Harrigal	CA	Diagnostic Radiology Physician	$1.3M	$1.1K
Juan Cattoni	NV	Hematology & Oncology Physician	$1.2M	$240
Vodur Reddy	NV	Hematology & Oncology Physician	$1M	$0

Nearby Providers

Other providers in the same ZIP code as Emily Guerard, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Kuhn Physical Therapy LLC	NV	Physical Therapist	$0	$13.1M
Elena Geraymovych	NV	Ophthalmology Physician	$4.1M	$16.9K
Routt Dialysis LLC	NV	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$3.6M
Nevada Emergency Physicians PLLC	NV	Emergency Medicine Physician	$0	$3.3M
Eye Surgery Center Of Northern Nevada, LLC	NV	Ambulatory Surgical Clinic/Center	$2.7M	$114.7K
Steven Friedlander	NV	Ophthalmology Physician	$2.4M	$376.5K
Culpepper Psychiatric Associates PLLC	NV	Community Health Clinic/Center	$0	$2.6M
Liberty Dialysis-south Reno LLC	NV	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$2.5M
Saint Marys Urgent Care LLC	NV	Multi-Specialty Clinic/Center	$0	$2.3M
Bennett Medical Services	NV	Oxygen Equipment & Supplies (DME)	$0	$2.1M

Emily Guerard — Billing Profile & Reimbursement Data

Sign up for Emily Guerard — Billing Profile & Reimbursement Data policy alerts

Emily Guerard — Billing Profile & Reimbursement Data

Sign up for Emily Guerard — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References